Sartorius Stedim Biotech Forecast, price target & analysts
Sartorius Stedim Biotech Target price 2025 - Analyst rating & recommendation
Sartorius Stedim Biotech Classifications & Recommendation:
Sartorius Stedim Biotech Price Target
| Target Price | €244.80 |
| Price | €204.60 |
| Potential |
19.65%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Sartorius Stedim Biotech 2026 .
The average Sartorius Stedim Biotech target price is €244.80.
This is
19.65%
register free of charge
€263.55
28.81%
register free of charge
€212.10
3.67%
register free of charge
|
|
| A rating was issued by 18 analysts: 13 Analysts recommend Sartorius Stedim Biotech to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sartorius Stedim Biotech stock has an average upside potential 2026 of
19.65%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 2.78 | 3.03 |
| 0.16% | 8.92% | |
| EBITDA Margin | 25.16% | 29.97% |
| 1.36% | 19.13% | |
| Net Margin | 6.30% | 13.94% |
| 43.55% | 121.32% |
15 Analysts have issued a sales forecast Sartorius Stedim Biotech 2025 . The average Sartorius Stedim Biotech sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Sartorius Stedim Biotech EBITDA forecast 2025. The average Sartorius Stedim Biotech EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Sartorius Stedim Biotech Analysts have issued a net profit forecast 2025. The average Sartorius Stedim Biotech net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 1.81 | 4.34 |
| 46.13% | 139.78% | |
| P/E | 47.15 | |
| EV/Sales | 7.28 |
16 Analysts have issued a Sartorius Stedim Biotech forecast for earnings per share. The average Sartorius Stedim Biotech EPS is
This results in the following potential growth metrics and future valuations:
Sartorius Stedim Biotech...
Current Sartorius Stedim Biotech Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ESN/CIC MARKET SOLUTIONS |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| HSBC |
Locked
➜
Locked
|
Locked | Mar 23 2025 |
| NEPHRON RESEARCH |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
| HSBC |
Locked
➜
Locked
|
Locked | Nov 24 2024 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
ESN/CIC MARKET SOLUTIONS:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
HSBC:
Locked
➜
Locked
|
Mar 23 2025 |
|
Locked
NEPHRON RESEARCH:
Locked
➜
Locked
|
Jan 30 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Jan 29 2025 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Jan 27 2025 |
|
Locked
HSBC:
Locked
➜
Locked
|
Nov 24 2024 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Nov 18 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
